<p>Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy</p>
- DOI
- 10.2147/copd.s265037
- Published
- 2020-10
- Container
- International Journal of Chronic Obstructive Pulmonary Disease
- Publisher
- Informa UK Limited
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.2147/copd.s265037,
title = {\<p\>Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy\</p\>},
author = {Chad Moretz and Beth Hahn and John White and Alyssa Goolsby Hunter and Breanna Essoi and Caitlin Elliott and Riju Ray},
year = {2020},
journal = {International Journal of Chronic Obstructive Pulmonary Disease},
doi = {10.2147/copd.s265037},
url = {https://doi.org/10.2147/copd.s265037}
}RIS
TY - JOUR TI - <p>Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy</p> AU - Chad Moretz AU - Beth Hahn AU - John White AU - Alyssa Goolsby Hunter AU - Breanna Essoi AU - Caitlin Elliott AU - Riju Ray PY - 2020 JO - International Journal of Chronic Obstructive Pulmonary Disease DO - 10.2147/copd.s265037 UR - https://doi.org/10.2147/copd.s265037 ER -
APA
Moretz, C., Hahn, B., White, J., Hunter, A. G., Essoi, B., Elliott, C., & Ray, R. (2020). <p>Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy</p>. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s265037
Source records
- crossref · retrieved 2026-09-27T03:33:35.121Z